Tenaya Therapeutics Inc (TNYA)

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for heart disease in the United States. The company’s pipeline includes TN-201, a gene therapy candidate for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-401, a gene therapy candidate for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy; and TN-301, a small molecule HDAC6 program being studied for heart failure with preserved ejection fraction. These programs are in early clinical development, including Phase 1 and Phase 1b/2 trials. Tenaya’s research approach spans gene addition, gene editing, gene silencing, and cellular regeneration. The company also has a research collaboration with Alnylam Pharmaceuticals aimed at identifying and validating new gene targets for potential cardiovascular disease treatments. Tenaya was incorporated in 2016 and is headquartered in South San Francisco, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.